ExcelMale Men's Health Forum Podcast Por NELSON VERGEL arte de portada

ExcelMale Men's Health Forum

ExcelMale Men's Health Forum

De: NELSON VERGEL
Escúchala gratis

Obtén 3 meses por US$0.99 al mes + $20 crédito Audible
This podcast series was created for the website www.ExcelMale.com, the leading and best-moderated men's health forum focused on increasing health, potency and productivity in men.All rights reserved. No portion of this podcast may be reproduced in any form without permission from the publisher, except as permitted by U.S. copyright law. For permissions contact: https://www.excelmale.com/contact-us/ Desarrollo Personal Higiene y Vida Saludable Éxito Personal
Episodios
  • Why It's Taking So Long (Or Not Happening At All): The Men's Health Issue No One Talks About

    Why It's Taking So Long (Or Not Happening At All): The Men's Health Issue No One Talks About
    Nov 15 2025

    You've heard endless discussions about ED and premature ejaculation, but there's a sexual health issue affecting millions of men that rarely gets airtime: difficulty reaching orgasm—or not being able to finish at all.

    If you've noticed things are taking longer than they used to, or you're struggling to cross the finish line despite wanting to, you're not alone. And more importantly, it's not just "in your head."

    In this episode, we break down:

    • The real reasons this happens—from medications you might already be taking (yes, including common antidepressants) to hormonal imbalances and psychological factors most guys never consider
    • Why your doctor probably hasn't brought this up, and the specific questions you need to ask
    • Treatment approaches that actually work, including when to push for medication changes and what combination therapies show real promise
    • Emerging pharmacological options that researchers are excited about—and what's missing from the current medical toolkit
    • Why getting a proper diagnosis requires more than a quick office visit

    The uncomfortable truth: There's no FDA-approved treatment specifically for this condition, and most healthcare providers aren't trained to address it properly. That means you need to advocate for yourself.

    Whether you're dealing with this now or want to understand the warning signs before they become a problem, this episode gives you the knowledge to take control.

    Listen now and stop wondering what's going wrong.
    Más Menos
    7 m
  • Painkiller NSAIDs Boost Muscle Growth, Not Strength, in Trained Men

    Painkiller NSAIDs Boost Muscle Growth, Not Strength, in Trained Men
    Nov 3 2025
    This episode reviews a 2025 research article in "The Journal of Physiology," authored by Mallinson et al., which investigates the effects of Non-Steroidal Anti-Inflammatory Drug (NSAID) ingestion alongside resistance exercise training (RET) in trained men. The study, a randomized, placebo-controlled, double-blind experiment, found that daily consumption of diclofenac over 84 days augmented muscle hypertrophy (increased muscle cross-sectional area and volume) compared to a placebo, particularly between days 28 and 84 of training. Notably, this increased muscle size was not accompanied by greater gains in muscle strength or increased total workout output, suggesting the NSAID enhanced the molecular signals for muscle growth but did not translate to superior functional performance. The researchers observed that gene networks linked to muscle growth and metabolism were more profoundly altered in the NSAID group, indicating a differential effect on muscle mRNA expression. Despite the muscle size benefits, the authors conclude that recommending chronic NSAID use for enhancing sports performance is inadvisable due to the lack of strength improvement and known adverse effects, though it might aid muscle mass restoration after injury.
    Más Menos
    16 m
  • How Compounding Pharmacies Are Challenging Big Pharma on Fair Access

    How Compounding Pharmacies Are Challenging Big Pharma on Fair Access
    Jul 8 2025
    This podcast discussion examines the burgeoning role of compounding pharmacies, particularly in the context of GLP-1 medications, and how they are challenging the established dominance of Big Pharma. Driven by soaring drug costs, supply shortages, and a demand for personalized medicine, compounding pharmacies, often in partnership with telehealth platforms, are offering a more affordable and accessible alternative. This shift is exposing "cracks in the FDA's regulatory system" and leading to a "proxy war for the future of medicine" between traditional pharmaceutical companies and this disruptive new model. The core themes revolve around access vs. oversight, the economic implications of drug pricing, and the legal and narrative battles over drug patents and public perception. Discussion FAQS: What are compounded GLP-1 medications and why are they gaining popularity? Compounded GLP-1 medications are custom-formulated versions of drugs like semaglutide and tirzepatide (known by brand names like Ozempic, Wegovy, Zepbound, and Mounjaro). They are gaining popularity because they offer a lower-cost, more accessible alternative to brand-name drugs, especially amidst skyrocketing demand, high prices (around $1,000/month in the U.S. compared to $100 elsewhere), and persistent shortages of the original medications. Compounding pharmacies can tailor these medications by adjusting doses, removing allergens, or creating combinations not available from Big Pharma, catering to individual patient needs that the "one-size-fits-all" industrial model often overlooks. How are compounding pharmacies challenging traditional pharmaceutical companies (Big Pharma)? Compounding pharmacies challenge Big Pharma in several ways. Firstly, they offer a direct-to-patient model, often through telehealth platforms, bypassing the intermediaries (PBMs, wholesalers, insurance layers) that add significant cost to brand-name drugs. Secondly, they provide customized solutions to address issues like rigid dose formulations, chronic shortages, and the high cost of brand-name drugs, which Big Pharma's model struggles with. Lastly, some compounders, like Empower Pharmacy, are directly challenging Big Pharma's intellectual property by petitioning to invalidate drug patents, aiming to open the market for broader access regardless of FDA shortage statuses. What are the main regulatory concerns and challenges associated with compounded medications? The primary regulatory challenge lies in balancing access with safety. While compounded medications offer flexibility and affordability, they operate within regulatory "gray zones." The FDA's current framework, designed for a pre-telehealth era, struggles to oversee hybrid telehealth-compounding platforms. Concerns include the use of non-equivalent salt forms, inconsistent quality, and sourcing issues, particularly when some compounders have mass-produced medications in ways that skirt individual prescription rules. State boards also have varying enforcement standards, further complicating oversight. How has the rise of telehealth platforms impacted the compounding industry? Telehealth platforms have been instrumental in the re-emergence and mainstreaming of compounding. Companies like Hims & Hers and BlueChew have leveraged telehealth to offer compounded medications directly to consumers, emphasizing convenience, customization, and discretion. These platforms have rebranded compounding as a tech-enabled, consumer-first digital health service, expanding its reach beyond niche use cases into categories like GLP-1s, dermatology (e.g., Musely), and hormone replacement therapy. Telehealth has made medicine "borderless," pushing regulatory bodies to catch up with the rapid evolution of healthcare delivery. What role has public perception and "misinformation" played in the debate between Big Pharma and compounders? Big Pharma has actively engaged in a "misinformation machine" to shape public opinion and state-level regulations against compounded GLP-1s. After the FDA declared shortages resolved, pharmaceutical companies focused on controlling the narrative through media stories warning of "fake Ozempic" and dangers associated with compounded drugs. These articles often blurred the lines between illicit, unregulated imports and legitimate 503A or 503B licensed compounders. Industry-backed groups supplied data and patient stories that conflated the two, leading to pressure on state regulators to adopt restrictive legislation that would effectively ban personalized compounded options. What is "evergreening" in the context of drug patents, and how does it relate to Big Pharma's dominance? "Evergreening" is a tactic used by pharmaceutical companies to extend their monopolies on drugs. It involves making minor tweaks to existing drugs or obtaining additional patents on aspects of a drug (like new formulations or uses) to prolong their exclusivity beyond the initial patent expiration. This practice, often ...
    Más Menos
    13 m
Todavía no hay opiniones